Birth outcomes following prenatal exposure to fluoxetine

Biological Psychiatry

Volumn 48, Issue 10, 2000, Pages 996-1000

  Cohen, Lee S ^a   Heller, Vicki L ^b   Bailey, Jennie W ^a   Grush, Lynn ^a,c   Ablon, J Stuart ^a   Bouffard, Suzanne M ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c Franciscan Children's Hospital   (United States)

Author keywords

Depression; Fluoxetine; Perinatal outcome; Pregnancy

Indexed keywords

FLUOXETINE;

ARTICLE; BIRTH WEIGHT; CONTROLLED STUDY; DEPRESSION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEWBORN; NEWBORN CARE; NEWBORN PERIOD; PRENATAL EXPOSURE; PRIORITY JOURNAL; RELAPSE; SIDE EFFECT; TREATMENT OUTCOME;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; APGAR SCORE; BIRTH WEIGHT; FEMALE; FLUOXETINE; GESTATIONAL AGE; HUMANS; INFANT, NEWBORN; PREGNANCY; PREGNANCY OUTCOME;

EID: 0034669412     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(00)00877-5     Document Type: Article

References (9)

1. Birth outcomes in pregnant women taking fluoxetine
2. Effects of third trimester fluoxetine exposure on the newborn
3. Sex and depression in the National Comorbidity Survey I; Lifetime prevalence, chronicity and recurrence
4. Social support, life events, and depression during pregnancy and the pueperium
5. Controlled prospective study of postpartum mood disorders; Psychological, environmental, and hormonal factors
6. Maternal depressive symptoms and the risk of poor pregnancy outcome. Review of the literature and preliminary findings
7. Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac)
8. Pharmacologic treatment of depression during pregnancy